Negative spinal bone mineral density changes and subclinical ovulatory disturbances-prospective data in healthy premenopausal women with regular menstrual cycles

Epidemiologic Reviews

Volumn 36, Issue 1, 2014, Pages 137-147

  Li, Danni ^a   Hitchcock, Christine L ^a   Barr, Susan I ^a   Yu, Tricia ^a   Prior, Jerilynn C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

bone mineral density; osteoporosis risk; ovulatory disturbances; premenopause; progesterone

Indexed keywords

ARTICLE; BONE DENSITY; CANADA; ESTROGEN BLOOD LEVEL; HORMONAL REGULATION; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; META ANALYSIS; OSTEOLYSIS; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; SPINE; YOUNG ADULT;

BONE MINERAL DENSITY; OSTEOPOROSIS RISK; OVULATORY DISTURBANCES; PREMENOPAUSE; PROGESTERONE;

ADOLESCENT; ADULT; ANOVULATION; AUSTRALIA; BONE DENSITY; CALIFORNIA; CANADA; CAUSALITY; COMORBIDITY; ESTROGENS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LUTEAL PHASE; MENSTRUAL CYCLE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PREMENOPAUSE; PROGESTERONE; PROSPECTIVE STUDIES; SPINE; YOUNG ADULT;

EID: 84891546815     PISSN: 0193936X     EISSN: 14786729     Source Type: Journal    
DOI: 10.1093/epirev/mxt012     Document Type: Article

References (69)

1. Nicodemus KK, Folsom AR, Anderson KE. Menstrual history and risk of hip fractures in postmenopausal women the Iowa Women's Health Study. Am J Epidemiol. 2001;153(3): 251-255.
2. Cooper GS, Sandler DP. Long-term effects of reproductive-age menstrual cycle patterns on peri-and postmenopausal fracture risk. Am J Epidemiol. 1997;145(9):804-809.
3. Albright F, Bloomberg E, Smith PH. Postmenopausal osteoporosis. Trans Assoc Am Physicians. 1940;55:298-305.
4. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376(9744):911-921.
5. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980; 303(26):1511-1514.
6. Rigotti NA, Nussbaum SR, Herzog DB, et al. Osteoporosis in women with anorexia nervosa. N Engl J Med. 1984;311(25): 1601-1606.
7. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221-1230.
8. Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. J Osteoporos. 2010;2010: 845180.
9. Scheven BA, Damen CA, Hamilton NJ, et al. Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitro. Biochem Biophys Res Commun. 1992;186(1):54-60.
10. Schmidmayr M, Magdolen U, Tubel J, et al. Progesterone enhances differentiation of primary human osteoblasts in long-term cultures the influence of concentration and cyclicity of progesterone on proliferation and differentiation of human osteoblasts in vitro. Geburtshilfe Frauenheilkd. 2008;68(7): 722-728.
11. Tremollieres FA, Strong DD, Baylink DJ, et al. Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinol (Copenh). 1992;126(4):329-337.
12. Prior JC, Vigna YM, Barr SI, et al. Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med. 1994;96(6):521-530.
13. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial the Writing Group for the PEPI. JAMA. 1996; 276(17):1389-1396.
14. Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287(20):2668-2676.
15. Prior JC, Vigna YM, Schechter MT, et al. Spinal bone loss and ovulatory disturbances.NEngl J Med. 1990;323(18):1221-1227.
16. Prior JC. Exercise associated menstrual disturbances. In: Adashi EY, Rock JA, Rosenwaks Z, eds. Reproductive Endocrinology, Surgery and Technology. New York, NY: Raven Press; 1996:1077-1091.
17. Barr SI, Janelle KC, Prior JC. Vegetarian vs nonvegetarian diets, dietary restraint, and subclinical ovulatory disturbances: prospective 6-mo study. Am J Clin Nutr. 1994;60(6):887-894.
18. Nagata I, Kato K, Seki K, et al. Ovulatory disturbances. Causative factors among Japanese student nurses in a dormitory. J Adolesc Health Care. 1986;7(1):1-5.
19. Kaplan JR, Chen H, Appt SE, et al. Impairment of ovarian function and associated health-related abnormalities are attributable to low social status in premenopausal monkeys and not mitigated by a high-isoflavone soy diet. Hum Reprod. 2010; 25(12):3083-3094.
20. Khosla S, Melton LJ 3rd, Riggs BL the unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26(3):441-451.
21. Kalyan S, Prior JC. Bone changes and fracture related to menstrual cycles and ovulation. Crit Rev Eukaryot Gene Expr. 2010;20(3):213-233.
22. Prior JC, Vigna YM, Wark JD, et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res. 1997;12(11):1851-1863.
23. De Souza MJ, Miller BE, Sequenzia LC, et al. Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners. J Clin Endocrinol Metab. 1997;82(9):2867-2876.
24. Winters KM, Adams WC, Meredith CN, et al. Bone density and cyclic ovarian function in trained runners and active controls. Med Sci Sports Exerc. 1996;28(7):776-785.
25. Grewal J, Sowers MR, Randolph JF Jr, et al. Low bone mineral density in the early menopausal transition: role for ovulatory function. J Clin Endocrinol Metab. 2006;91(10): 3780-3785.
26. Sowers M, Randolph JF Jr, Crutchfield M, et al. Urinary ovarian and gonadotropin hormone levels in premenopausal women with low bone mass. J Bone Miner Res. 1998;13(7): 1191-1202.
27. Waugh EJ, Polivy J, Ridout R, et al. A prospective investigation of the relations among cognitive dietary restraint, subclinical ovulatory disturbances, physical activity, and bone mass in healthy young women. Am J Clin Nutr. 2007;86(6):1791-1801.
28. Bedford JL, Prior JC, Barr SI. A prospective exploration of cognitive dietary restraint, subclinical ovulatory disturbances, cortisol, and change in bone density over two years in healthy young women. J Clin Endocrinol Metab. 2010;95(7):3291-3299.
29. Morris FL, Payne WR,Wark JD the impact of intense training on endogenous estrogen and progesterone concentrations and bone mineral acquisition in adolescent rowers. Osteoporos Int. 1999;10(5):361-368.
30. Waller K, Reim J, Fenster L, et al. Bone mass and subtle abnormalities in ovulatory function in healthy women. J Clin Endocrinol Metab. 1996;81(2):663-668.
31. Prior JC, Vigna YM, Barr SI, et al. Ovulatory premenopausal women lose cancellous spinal bone: a five year prospective study. Bone. 1996;18(3):261-267.
32. Khan A, Syed Z. Bone mineral density assessment in premenopausal women. Womens Health (Lond Engl). 2006; 2(4):639-645.
33. Khan A. Premenopausal women and low bone density. Can Fam Physician. 2006;52(6):743-747.
34. Henley K, Vaitukaitis JL. Exercise-induced menstrual dysfunction. Annu Rev Med. 1988;39:443-451.
35. Park KH, Song CH. Bone mineral density in premenopausal anovulatory women. J Obstet Gynaecol (Tokyo 1995). 1995; 21(1):89-97.
36. Papanek PE the female athlete triad: an emerging role for physical therapy. J Orthop Sports Phys Ther. 2003;33(10): 594-614.
37. Landgren BM, Unden AL, Diczfalusy E. Hormonal profile of the cycle in 68 normally menstruating women. Acta Endocrinol (Copenh). 1980;94(1):89-98.
38. Prior JC, Vigna YM, Schulzer M, et al. Determination of luteal phase length by quantitative basal temperature methods: validation against the midcycle LH peak. Clin Invest Med. 1990;13(3):123-131.
39. Vollman RF the menstrual cycle. In: Major Problems in Obstetrics and Gynecology. Vol 7. Toronto, Canada: WB Saunders Company; 1977.
40. Harris RJ, Bradburn MJ, Deeks JJ, et al. Metan: fixed-and random-effects meta-analysis. Stata J. 2008;8(1):3-28.
41. Khan A. Management of low bone mineral density in premenopausal women. J Obstet Gynaecol Can. 2005;27(4): 345-349.
42. Volpe A, Malmusi S, Zanni AL, et al. Oral contraceptives and bone metabolism. Eur J Contracept Reprod Health Care. 1997; 2(4):225-228.
43. Petit MA, Prior JC, Barr SI, et al. An unsuccessful attempt to relate ovulatory disturbances to changes in bone density. J Clin Endocrinol Metab. 1996;81(11):4176-4179.
44. Greene JW. Exercise-induced menstrual irregularities. Compr Ther. 1993;19(3):116-120.
45. Cirkel U, Schweppe KW, Ochs H, et al. LH-RH agonist (buserelin): treatment of endometriosis. Clinical, laparoscopic, endocrine and metabolic evaluation. Arch Gynecol Obstet. 1989;246(3):139-151.
46. Glintborg D, Andersen M. Thiazolinedione treatment in PCOS-an update. Gynecol Endocrinol. 2010;26(11):791-803.
47. Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril. 1996;65(1):23-28.
48. Ladson G, Dodson WC, Sweet SD, et al. Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study. Fertil Steril. 2011;96(1):224-229.
49. Zamberlan N, Castello R, Gatti D, et al. Intermittent etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist. Osteoporos Int. 1997;7(2):133-137.
50. McLean JA, Barr SI, Prior JC. Dietary restraint, exercise, and bone density in young women: are they related? Med Sci Sports Exerc. 2001;33(8):1292-1296.
51. Barr SI, Prior JC, Vigna YM. Restrained eating and ovulatory disturbances: possible implications for bone health. Am J Clin Nutr. 1994;59(1):92-97.
52. Burger HG the menopausal transition. Baillieres Clin Obstet Gynaecol. 1996;10(3):347-359.
53. Rannevik G, Jeppsson S, Johnell O, et al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas. 2008;61(1-2):67-77.
54. Bedford JL, Prior JC, Hitchcock CL, et al. Detecting evidence of luteal activity by least-squares quantitative basal temperature analysis against urinary progesterone metabolites and the effect of wake-time variability. Eur J Obstet Gynecol Reprod Biol. 2009;146(1):76-80.
55. McConnell HJ, O'Connor KA, Brindle E, et al. Validity of methods for analyzing urinary steroid data to detect ovulation in athletes. Med Sci Sports Exerc. 2002;34(11):1836-1844.
56. Kassam A, Overstreet JW, Snow-Harter C, et al. Identification of anovulation and transient luteal function using a urinary pregnanediol-3- glucuronide ratio algorithm. Environ Health Perspect. 1996;104(4):408-413.
57. Yu EW, Thomas BJ, Brown JK, et al. Simulated increases in body fat and errors in bone mineral density measurements by DXA and QCT. J Bone Miner Res. 2012;27(1):119-124.
58. Tanno M, Horiuchi T, Ogihara M, et al. Comparative study of bone mineral density estimated by various methods of singleand dual-energy quantitative computed tomography: the capability of the four-equation four-unknown method. Bone. 1996;18(3):239-247.
59. Prior JC, Naess M, Langhammer A, et al the point prevalence of ovulation in a large population-based sample of spontaneously, regularly menstruating women the HUNT Study. Presented at the 95th Annual Meeting of the Endocrine Society, San Francisco, CA, June 15-18, 2013.
60. Schmidt FL, Oh IS, Hayes TL. Fixed-versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62(Pt 1):97-128.
61. O'Connor KA, Brindle E, Miller RC, et al. Ovulation detection methods for urinary hormones: precision, daily and intermittent sampling and a combined hierarchical method. Hum Reprod. 2006;21(6):1442-1452.
62. Weiss G. Understanding the perimenopause. Womens Health (Lond Engl). 2007;3(4):387-390.
63. Kassanos D, Trakakis E, Baltas CS, et al. Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study. Hum Reprod. 2010;25(8): 2107-2114.
64. Yanazume Y, Kawamura Y, Kuwahata A, et al. Difference in non-weight-bearing effects on bone mineral density between trunk and peripheral fat mass in women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2010; 36(2):352-356.
65. Hergenroeder AC, Smith EO, Shypailo R, et al. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol. 1997;176(5): 1017-1025.
66. Seifert-Klauss V, Kingwell E, Hitchcock CL, et al. Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause. 2008;15(1):203; author reply 203-204.
67. Liu JH, Muse KN the effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol. 2005;192(4):1316-1323; discussion 1323-1314.
68. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87(4): 1586-1592.
69. Prior JC the aging female reproductive axis II: ovulatory changes with perimenopause. In: Chadwick DJ, Goode JA, eds. Endocrine Facets of Aging. Chichester, United Kingdom: Wiley; 2002:172-192.